NO20072576L - CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer - Google Patents

CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer

Info

Publication number
NO20072576L
NO20072576L NO20072576A NO20072576A NO20072576L NO 20072576 L NO20072576 L NO 20072576L NO 20072576 A NO20072576 A NO 20072576A NO 20072576 A NO20072576 A NO 20072576A NO 20072576 L NO20072576 L NO 20072576L
Authority
NO
Norway
Prior art keywords
breast cancer
antibody
aromatase inhibitor
ctla
combination therapy
Prior art date
Application number
NO20072576A
Other languages
Norwegian (no)
Inventor
Jesus Gomez-Navarro
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20072576L publication Critical patent/NO20072576L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører administrering av et anti-CTLA4-antistoff, spesielt humane antistoffer mot humant CTLA4, slik som de som har aminosyresekvenser til antistoffer 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9. 1.1 og I ODI (MDX-010), i kombinasjon med en aromatasehemmer, for behandlingen av brystcancer. Mer bestemt vedrører oppfinnelsen administrering av et anti-CTLA4antistoff og eksemestan for behandling av brystcancer.This invention relates to the administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences for antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9. 1.1 and I ODI (MDX-010), in combination with an aromatase inhibitor, for the treatment of breast cancer. More particularly, the invention relates to administration of an anti-CTLA4 antibody and eczema to the treatment of breast cancer.

NO20072576A 2004-11-04 2007-05-21 CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer NO20072576L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04
PCT/IB2005/003307 WO2006048749A1 (en) 2004-11-04 2005-10-24 Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Publications (1)

Publication Number Publication Date
NO20072576L true NO20072576L (en) 2007-08-03

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072576A NO20072576L (en) 2004-11-04 2007-05-21 CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer

Country Status (15)

Country Link
EP (1) EP1819735A1 (en)
JP (1) JP2008518902A (en)
KR (1) KR20070067702A (en)
CN (1) CN101052655A (en)
AR (1) AR053651A1 (en)
AU (1) AU2005300315A1 (en)
BR (1) BRPI0515735A2 (en)
CA (1) CA2586844A1 (en)
IL (1) IL182244A0 (en)
MX (1) MX2007003804A (en)
NO (1) NO20072576L (en)
RU (1) RU2007114111A (en)
TW (1) TW200621804A (en)
WO (1) WO2006048749A1 (en)
ZA (1) ZA200702577B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937251A2 (en) * 2005-04-25 2008-07-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
KR20080030656A (en) * 2005-07-07 2008-04-04 콜레이 파마시티컬 그룹, 인코포레이티드 Combination therapy of anti-CTLA-4 antibody and CVII-motif-containing oligodeoxynucleotide for the treatment of cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
JP2011509299A (en) 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー Combination of anti-CTLA-4 antibody and tubulin modulator for the treatment of proliferative diseases
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN102227503B (en) 2008-09-26 2015-10-21 托卡根公司 recombinant vector
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
NO2344540T3 (en) 2008-10-02 2018-04-28
PT2769737T (en) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co COMBINATION OF AN ANTI-CTLA4 ANTIBODY WITH ETOPÓSIDO FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
EP3431142B1 (en) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
IL301603A (en) * 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, Trastuzumab, Docetaxel and Carboplatin for use in neoadjuvant treatment of a patient
RU2737765C2 (en) 2012-05-04 2020-12-02 Пфайзер Инк. Prostate-associated antigens and immunotherapeutic regimens based on vaccines
CN103768596B (en) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 For the combination product of oncotherapy, its purposes and correlation technique
ES2786051T3 (en) 2012-10-25 2020-10-08 Tocagen Inc Retroviral vector with mini-promoter cassette
CA2902433A1 (en) 2013-03-01 2014-09-04 Astex Pharmaceuticals, Inc. Drug combinations
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
JP2018526007A (en) 2015-09-04 2018-09-13 トカジェン インコーポレーテッド Recombinant vector containing 2A peptide
CN106883298B (en) * 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 Bispecific conjugated antibodies, methods of making and uses thereof
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
RU2769282C2 (en) 2016-06-20 2022-03-30 Кимаб Лимитед Anti-pd-l1 and il-2 cytokines
WO2018037595A1 (en) * 2016-08-26 2018-03-01 哲治 奥野 Microvascular blood flow decreasing agent and use thereof
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
PT3589661T (en) 2017-03-02 2024-01-29 Genentech Inc Adjuvant treatment of her2-positive breast cancer
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
RU2020108580A (en) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. MEDICINAL COMPOUNDS AND METHODS OF ITS PURIFICATION
EP4110347A4 (en) * 2020-02-27 2024-05-29 University of Washington Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
ZA200702577B (en) 2008-07-30
CA2586844A1 (en) 2006-05-11
BRPI0515735A2 (en) 2011-10-11
WO2006048749A1 (en) 2006-05-11
KR20070067702A (en) 2007-06-28
EP1819735A1 (en) 2007-08-22
JP2008518902A (en) 2008-06-05
AU2005300315A1 (en) 2006-05-11
MX2007003804A (en) 2007-04-23
TW200621804A (en) 2006-07-01
CN101052655A (en) 2007-10-10
RU2007114111A (en) 2008-12-10
IL182244A0 (en) 2007-09-20
AR053651A1 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
NO20072576L (en) CTLA-4 antibody and aromatase inhibitor or combination therapy for breast cancer
WO2007113648A3 (en) Ctla4 antibody combination therapy
NO20056236L (en) Treatment with anti-VEGF antibodies
MX2010005651A (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof.
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
CY1115745T1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF OXALIC DISEASES
UA108193C2 (en) APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
NO20054769L (en) Substituted phenylalkanoic acids
CY1113243T1 (en) METHODS OF TREATMENT USING CTLA-4
MX2011006685A (en) Membrane type-1 matrix metalloprotein inhibitors and uses thereof.
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
UY31114A1 (en) HUMANIZED ANTIBODIES AGAINST AB GLOBULOMER (20-42) AND ITS USES
DK1468014T3 (en) Compositions and Methods for WT1-Specific Immunotherapy
CY1117655T1 (en) FACTORS AFFECTING CANCER AND IMMUNE AND AUTOMATIC DISEASES TREATMENT
NO20054958L (en) Substituted amino carboxylic acids
NO20055894L (en) Methods and compositions for the treatment of amyloid-related diseases
EA201000424A1 (en) ANTIBODIES TO IL-23
CY1116728T1 (en) FACTORS AFFECTING CANCER AND IMMUNE AND AUTOMATIC DISEASES TREATMENT
ECSP045520A (en) TREATMENT METHODS WITH PTEC INHIBITORS AND ANTIHIPERTENSIVE AGENTS
NO20070091L (en) Sugar coating and method for this
NO341574B1 (en) Compound, pharmaceutical composition and kits for treating cancer or in an imaging method.
NO20062876L (en) Compositions for combined radio and chemotherapy, and methods
NO20075849L (en) Methods and Preparations for the Treatment or Prevention of Cancer
EP4596042A3 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application